NasdaqGS:APYX

Stock Analysis Report

Executive Summary

Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Apyx Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.7%

APYX

1.9%

US Medical Equipment

0.4%

US Market


1 Year Return

29.6%

APYX

15.6%

US Medical Equipment

6.9%

US Market

Return vs Industry: APYX exceeded the US Medical Equipment industry which returned 15.6% over the past year.

Return vs Market: APYX exceeded the US Market which returned 6.9% over the past year.


Shareholder returns

APYXIndustryMarket
7 Day-2.7%1.9%0.4%
30 Day-7.2%-1.6%-1.2%
90 Day7.0%0.01%-0.4%
1 Year29.6%29.6%16.5%15.6%9.3%6.9%
3 Year46.7%46.7%72.1%66.9%45.8%36.4%
5 Year63.8%63.8%125.8%100.8%62.9%45.1%

Price Volatility Vs. Market

How volatile is Apyx Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Apyx Medical undervalued compared to its fair value and its price relative to the market?

2.84x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate APYX's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate APYX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: APYX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: APYX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate APYX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APYX is good value based on its PB Ratio (2.8x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Apyx Medical forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-29.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APYX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APYX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APYX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APYX's revenue (35.3% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: APYX's revenue (35.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if APYX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Apyx Medical performed over the past 5 years?

-9.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: APYX is unprofitable, and losses have increased over the past 5 years at a rate of -9.6% per year.

Accelerating Growth: Unable to compare APYX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APYX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: APYX has a negative Return on Equity (-15.87%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: APYX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: APYX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Apyx Medical's financial position?


Financial Position Analysis

Short Term Liabilities: APYX's short term assets ($82.0M) exceeds its short term liabilities ($7.9M)

Long Term Liabilities: APYX's short term assets (82.0M) exceeds its long term liabilities (407.0K)


Debt to Equity History and Analysis

Debt Level: APYX's debt to equity ratio (0.2%) is considered satisfactory

Reducing Debt: APYX's debt to equity ratio has reduced from 28.8% to 0.2% over the past 5 years.


Balance Sheet

Inventory Level: APYX has a low level of unsold assets or inventory.

Debt Coverage by Assets: APYX's debt is covered by short term assets (assets are 585.407140x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APYX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: APYX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -83.1% each year


Next Steps

Dividend

What is Apyx Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate APYX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate APYX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if APYX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APYX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APYX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Apyx Medical's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Charlie Goodwin (53yo)

1.8yrs

Tenure

US$1,489,733

Compensation

Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Bovie Medical Corporation since December 15, 2017 and serves as its President. Mr, Goodwin has a demonstra ...


CEO Compensation Analysis

Compensation vs. Market: Charlie has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Charlie's compensation has been consistent with company performance over the past year.


Management Age and Tenure

0.8yrs

Average Tenure

51yo

Average Age

Experienced Management: APYX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

2.3yrs

Average Tenure

68yo

Average Age

Experienced Board: APYX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Moshe Citronowicz (66yo)

    Senior Vice President

    • Tenure: 0yrs
    • Compensation: US$588.32k
  • Charlie Goodwin (53yo)

    President

    • Tenure: 1.8yrs
    • Compensation: US$1.49m
  • Todd Hornsby (43yo)

    Executive Vice President

    • Tenure: 0.8yrs
    • Compensation: US$504.10k
  • Tara Semb (49yo)

    CFO, Treasurer & Secretary

    • Tenure: 0.8yrs

Board Members

  • Andrew Makrides (77yo)

    Chairman of the Board

    • Tenure: 5.8yrs
    • Compensation: US$86.43k
  • Mike Geraghty (72yo)

    Independent Director

    • Tenure: 8.6yrs
    • Compensation: US$112.86k
  • Larry Waldman (73yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$142.86k
  • Greg Konesky (65yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: US$9.30k
  • Yuval Carmel

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Charlie Goodwin (53yo)

    President

    • Tenure: 1.8yrs
    • Compensation: US$1.49m
  • John Andres (61yo)

    Independent Vice-Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$139.36k
  • Minnie Baylor-Henry (71yo)

    Director

    • Tenure: 0.2yrs
  • Craig Swandal (58yo)

    Independent Director

    • Tenure: 1.6yrs
    • Compensation: US$120.42k
  • Dennis Chi

    Member of Medical Advisory Board

    • Tenure: 2.8yrs

Company Information

Apyx Medical Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Apyx Medical Corporation
  • Ticker: APYX
  • Exchange: NasdaqGS
  • Founded: 1982
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$228.970m
  • Shares outstanding: 33.92m
  • Website: https://apyxmedical.com

Number of Employees


Location

  • Apyx Medical Corporation
  • 5115 Ulmerton Road
  • Clearwater
  • Florida
  • 33760
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APYXNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJul 1983
BOVDB (Deutsche Boerse AG)YesCommon SharesDEEURJul 1983

Biography

Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 23:33
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.